Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

Abstract

Objective: Evaluate the overall survival (OS) of patients with multiple myeloma (MM) at different treatment stages in France. Methods: This retrospective observational cohort study used data from the French National Health Insurance database to study patients with MM (diagnosis 2013-2019). Patient outcomes included OS (all-cause mortality), time-to-next treatment (TTNT), and duration of therapy (DoT) from initial diagnosis, the start of different lines of therapy (LOTs), triple-class exposure (TCE), and subsequent treatment following TCE. The Kaplan-Meier method analyzed "time-to-event" data. Results: From diagnosis, death rates increased from 1% at 1 month to 24% at 2 years; median OS was 63.8 months (N = 14 309). Median OS from the start of LOTs declined from 61.0 months (LOT1) to 14.8 months (LOT4). Median OS from TCE start was 14.7 months. There was a large variation in TTNT within LOTs (e.g., LOT1: bortezomib + lenalidomide: TTNT = 26.4 months, OS = 61.7 months; lenalidomide: TTNT = 20.0 months, OS = 39.6 months); DoT was similar for LOT1 and LOT2, then progressively declined at LOT4. Patients with stem cell transplant, younger age, and less comorbidity had better survival outcomes. Conclusions: Patients with MM face a poor prognosis after relapse to multiple LOTs and TCE, demonstrating a worsening of survival outcomes. Access to novel therapies may improve outcomes.

Multiple Myeloma Rather Than Metastatic Lung Cancer: An Unexpected Cause of Spinal Cord Compression

“…Furthermore, daratumumab plus lenalidomide and dexamethasone increased the prognosis in patients with newly diagnosed MM [19]. In addition, there are currently other treatment options for younger patients, including bortezomib, lenalidomide, dexamethasone (+/-), daratumumab with/without consolidating high-dose chemotherapy, and autologous stem cell transplantation [20]. Moreover, daratumumab has been reported to be safe and effective for MM with LC, displayed benefits in survival and can induce complete remission to proceed to LC surgery [21,22].…”

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma

“…It is the second most common hematological malignancy in many countries [ 2 – 4 ] and has a substantial impact on public health. The specific incidence of MM in China is not clear, but the median age of onset is 57.9–59 years old [ 5 , 6 ], which is far lower than that observed in western countries [ 7 – 9 ]. In recent years, new chemotherapies and immune drugs have greatly improved the remission rate and survival time in MM [ 4 ].…”

Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study

“…Multiple myeloma (MM) is a malignant plasma cell infiltration of the bone marrow accounting for 1%–1.8% of all cancers, with an estimated incidence in Europe of 4.5–6.0/100 000/year 1 . Despite significant therapeutic advances over the past 10 years in management of MM, MM remains incurable and is the second most common hematologic malignancy, with 6967 new cases and 3720 deaths recorded in France and a 5‐year prevalence of 18 442 cases across all ages in 2020 2 . Most patients relapse or become refractory to treatments and require further therapy 3,4 …”